Eurofins-Cerep SA (ALECR.PA) Holds €16,100 as Healthcare Diagnostics Stabilize

Eurofins-Cerep SA (ALECR.PA) trades flat at €16,100 on EURONEXT today, showing resilience in the healthcare diagnostics sector. The French drug discovery specialist, based in Vienne, provides critical research services to pharmaceutical and biotech firms worldwide. With a market cap of €81.2 million and 2,090 employees, ALECR.PA stock reflects broader healthcare sector pressures. Meyka AI rates ALECR.PA stock with a B grade, suggesting a hold position for investors monitoring this medical diagnostics play.

ALECR.PA Stock Price and Technical Position

Eurofins-Cerep SA trades at €16,100, unchanged from yesterday’s close on EURONEXT. The stock sits below its 50-day average of €17,084 and 200-day average of €18,066, indicating downward pressure over recent months. Year-to-date, ALECR.PA stock has declined 9.55%, while the 12-month loss stands at 21.84%. Trading volume remains thin at just 5 shares, typical for smaller-cap healthcare stocks. The year-high of €20,600 and year-low of €15,800 frame a 23% trading range, showing volatility in this niche diagnostics segment.

Financial Metrics and Valuation for ALECR.PA Analysis

ALECR.PA stock trades at a P/E ratio of 16.99, below the healthcare sector average of 27.32, suggesting relative value. The company reports EPS of €947.64 and a price-to-sales ratio of 2.09, indicating modest premium pricing. Book value per share stands at €14,579.70, with the stock trading at 1.10x book value. Net profit margin reaches 15.87%, reflecting solid operational efficiency in drug discovery services. The current ratio of 8.34 demonstrates strong liquidity, while debt-to-equity remains negligible at 0.001, showing fortress-like balance sheet strength.

Meyka AI Grade and Investment Outlook

Meyka AI rates ALECR.PA with a grade of B, reflecting a neutral hold recommendation. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The rating details show strong scores in ROA (4/5) and debt management (4/5), offset by neutral DCF and P/E assessments. These grades are not guaranteed and we are not financial advisors. Track ALECR.PA on Meyka for real-time updates on this healthcare diagnostics stock.

Eurofins-Cerep SA Price Forecast and Upside Potential

Meyka AI’s forecast model projects €23,171 for ALECR.PA stock within 12 months, implying 43.8% upside from current levels. The three-year forecast reaches €25,100, while the five-year target climbs to €27,050. These projections assume recovery in pharmaceutical R&D spending and sustained demand for drug discovery services. However, near-term headwinds from healthcare sector weakness and thin trading liquidity may delay upside realization. Investors should monitor earnings announcements and sector trends before committing capital to this small-cap play.

Final Thoughts

Eurofins-Cerep SA (ALECR.PA) remains a niche healthcare diagnostics play trading at €16,100 with solid fundamentals but challenged near-term momentum. The B-grade rating and strong balance sheet provide downside protection, while the 43.8% upside forecast offers long-term appeal for patient investors. Thin trading volume and sector headwinds warrant caution, making ALECR.PA stock suitable only for experienced healthcare sector specialists. Monitor quarterly earnings and pharmaceutical industry trends before building positions in this French drug discovery specialist.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.